These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 33933666)

  • 1. Development of novel measures for Alzheimer's disease prevention trials (NoMAD).
    Bell SA; Cohen HR; Lee S; Kim H; Ciarleglio A; Andrews H; Rivera AM; Igwe K; Brickman AM; Devanand DP; Harvey PD; Schneider LS; Goldberg TE
    Contemp Clin Trials; 2021 Jul; 106():106425. PubMed ID: 33933666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel measures of cognition and function for the AD spectrum in the Novel Measures for Alzheimer's Disease Prevention Trials (NoMAD) project: Psychometric properties, convergent validation, and contrasts with established measures.
    Kim H; Lee S; Levine A; Huber B; Andrews H; Kerner NA; Cohen D; Carlson S; Bell SA; Rivera AM; Gordon ML; Simoes S; Devanand DP; Brickman AM; Schneider LS; Harvey PD; Goldberg TE
    Alzheimers Dement; 2024 Aug; 20(8):5089-5101. PubMed ID: 38963127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
    Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
    Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychometric Evaluation of the Neuropsychological Test Battery in Individuals with Normal Cognition, Mild Cognitive Impairment, or Mild to Moderate Alzheimer's Disease: Results from a Longitudinal Study.
    Harrison JE; Rentz DM; Brashear HR; Arrighi HM; Ropacki MT; Liu E
    J Prev Alzheimers Dis; 2018; 5(4):236-244. PubMed ID: 30298182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
    Podhorna J; Krahnke T; Shear M; Harrison JE;
    Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation study of the Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog) for the Portuguese patients with mild cognitive impairment and Alzheimer's disease.
    Nogueira J; Freitas S; Duro D; Almeida J; Santana I
    Clin Neuropsychol; 2018; 32(sup1):46-59. PubMed ID: 29566598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.
    Bransby L; Lim YY; Ames D; Fowler C; Roberston J; Harrington K; Snyder PJ; Villemagne VL; Salvado O; Masters CL; Maruff P
    J Clin Exp Neuropsychol; 2019 Aug; 41(6):591-600. PubMed ID: 30924399
    [No Abstract]   [Full Text] [Related]  

  • 8. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychometric Properties of the Clinical Dementia Rating - Sum of Boxes and Other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population.
    McDougall F; Edgar C; Mertes M; Delmar P; Fontoura P; Abi-Saab D; Lansdall CJ; Boada M; Doody R
    J Prev Alzheimers Dis; 2021; 8(2):151-160. PubMed ID: 33569561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychometric Properties of Alzheimer's Disease Assessment Scale-Cognitive Subscale for Mild Cognitive Impairment and Mild Alzheimer's Disease Patients in an Asian Context.
    Zainal NH; Silva E; Lim LL; Kandiah N
    Ann Acad Med Singap; 2016 Jul; 45(7):273-83. PubMed ID: 27523508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial.
    Papp KV; Rofael H; Veroff AE; Donohue MC; Wang S; Randolph C; Grober E; Brashear HR; Novak G; Ernstrom K; Raman R; Aisen PS; Sperling R; Romano G; Henley D
    J Prev Alzheimers Dis; 2022; 9(2):255-261. PubMed ID: 35542998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog): Normative Data for the Portuguese Population.
    Nogueira J; Freitas S; Duro D; Tábuas-Pereira M; Guerreiro M; Almeida J; Santana I
    Acta Med Port; 2018 Feb; 31(2):94-100. PubMed ID: 29596768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel approaches to measuring neurocognitive functions in Alzheimer's disease clinical trials.
    Carlson S; Kim H; Devanand DP; Goldberg TE
    Curr Opin Neurol; 2022 Apr; 35(2):240-248. PubMed ID: 35175975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.
    Ayutyanont N; Langbaum JB; Hendrix SB; Chen K; Fleisher AS; Friesenhahn M; Ward M; Aguirre C; Acosta-Baena N; Madrigal L; Muñoz C; Tirado V; Moreno S; Tariot PN; Lopera F; Reiman EM
    J Clin Psychiatry; 2014 Jun; 75(6):652-60. PubMed ID: 24816373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An approach for estimating item sensitivity to within-person change over time: An illustration using the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog).
    Dowling NM; Bolt DM; Deng S
    Psychol Assess; 2016 Dec; 28(12):1576-1585. PubMed ID: 27046272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
    Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E
    Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
    Sampson EL; Jenagaratnam L; McShane R
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005380. PubMed ID: 24563468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: a new approach.
    Posner HB; Cano S; Carrillo MC; Selnes O; Stern Y; Thomas RG; Zajicek J; Hobart J;
    Alzheimers Dement; 2013 Feb; 9(1 Suppl):S56-60. PubMed ID: 23391006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
    Sampson EL; Jenagaratnam L; McShane R
    Cochrane Database Syst Rev; 2012 May; 5(5):CD005380. PubMed ID: 22592705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.
    Irizarry MC; Webb DJ; Bains C; Barrett SJ; Lai RY; Laroche JP; Hosford D; Maher-Edwards G; Weil JG
    J Alzheimers Dis; 2008 Jul; 14(3):301-11. PubMed ID: 18599956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.